




# PHARMACEUTICAL 2023

GRI BIO Inc.  
Rank 358 of 446





# PHARMACEUTICAL 2023

GRI BIO Inc.  
Rank 358 of 446

The relative strengths and weaknesses of GRI BIO Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GRI BIO Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 21% points. The greatest weakness of GRI BIO Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 146% points.

The company's Economic Capital Ratio, given in the ranking table, is -100%, being 144% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	4,152
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,810
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	2.0
Other Expenses	122
Other Liabilities	0
Other Net Income	26
Other Revenues	0
Property and Equipment	0
Research and Development	1,170
Selling, General and Administrative Expense	5,758

Output Variable	Value in 1000 USD
Assets	4,152
Liabilities	1,810
Expenses	7,050
Revenues	0
Stockholders Equity	2,342
Net Income	-7,024
Comprehensive Net Income	-7,023
Economic Capital Ratio	-100%